These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Trajectory of left ventricular geometry and diastolic dysfunction in hereditary transthyretin cardiac amyloidosis. Akatsuka T; Fujimoto N; Ishiyama M; Nakamori S; Imanaka-Yoshida K; Dohi K ESC Heart Fail; 2021 Aug; 8(4):3422-3426. PubMed ID: 34145794 [TBL] [Abstract][Full Text] [Related]
65. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308 [TBL] [Abstract][Full Text] [Related]
66. Targeted treatments of AL and ATTR amyloidosis. Chandrashekar P; Desai AK; Trachtenberg BH Heart Fail Rev; 2022 Sep; 27(5):1587-1603. PubMed ID: 34783948 [TBL] [Abstract][Full Text] [Related]
67. Strong positive light chain immunostaining in a patient with transthyretin amyloidosis. Chen J; Chen H; Zhou L; Liu D; Du F; Xiang H Hematology; 2023 Dec; 28(1):2244315. PubMed ID: 37551718 [TBL] [Abstract][Full Text] [Related]
68. Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. Lohrmann G; Pipilas A; Mussinelli R; Gopal DM; Berk JL; Connors LH; Vellanki N; Hellawell J; Siddiqi OK; Fox J; Maurer MS; Ruberg FL J Card Fail; 2020 Sep; 26(9):753-759. PubMed ID: 31805416 [TBL] [Abstract][Full Text] [Related]
69. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. González-López E; López-Sainz Á; Garcia-Pavia P Rev Esp Cardiol (Engl Ed); 2017 Nov; 70(11):991-1004. PubMed ID: 28870641 [TBL] [Abstract][Full Text] [Related]
70. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis. Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087 [TBL] [Abstract][Full Text] [Related]
72. Regression of left ventricular hypertrophy after tafamidis therapy in a patient with transthyretin amyloidosis variant. Yagi S; Yamazaki H; Kusunose K; Osaki Y; Ise T; Kadota M; Tserensonom M; Kawabata Y; Hara T; Ueno R; Saijo Y; Matsuura T; Yamaguchi K; Yamada H; Fukuda D; Soeki T; Wakatsuki T; Sata M J Med Invest; 2022; 69(3.4):320-322. PubMed ID: 36244789 [TBL] [Abstract][Full Text] [Related]
73. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. López-Sainz Á; de Haro-Del Moral FJ; Dominguez F; Restrepo-Cordoba A; Amor-Salamanca A; Hernandez-Hernandez A; Ruiz-Guerrero L; Krsnik I; Cobo-Marcos M; Castro V; Toquero-Ramos J; Lara-Pezzi E; Fernandez-Lozano I; Alonso-Pulpon L; González-López E; Garcia-Pavia P Amyloid; 2019 Sep; 26(3):156-163. PubMed ID: 31210553 [No Abstract] [Full Text] [Related]
74. Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy. He S; Tian Z; Guan H; Li J; Fang Q; Zhang S Orphanet J Rare Dis; 2019 Nov; 14(1):251. PubMed ID: 31718691 [TBL] [Abstract][Full Text] [Related]
75. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Sekijima Y; Uchiyama S; Tojo K; Sano K; Shimizu Y; Imaeda T; Hoshii Y; Kato H; Ikeda S Hum Pathol; 2011 Nov; 42(11):1785-91. PubMed ID: 21733562 [TBL] [Abstract][Full Text] [Related]
76. Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Fontana M; Banypersad SM; Treibel TA; Abdel-Gadir A; Maestrini V; Lane T; Gilbertson JA; Hutt DF; Lachmann HJ; Whelan CJ; Wechalekar AD; Herrey AS; Gillmore JD; Hawkins PN; Moon JC Radiology; 2015 Nov; 277(2):388-97. PubMed ID: 25997029 [TBL] [Abstract][Full Text] [Related]